Gilead has agreed to buy Ouro and its T-cell engagers for autoimmune diseases in a $2.2bn deal that may also revive its alliance with Galapagos.
AI predicts liver cancer risk with “high accuracy”
A machine learning algorithm could serve as a pre-screen for hepatocellular carcinoma that identifies patients missed by current narrow guidance.

